Evidence map›Paper›PMID 39298681›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2024

Increasing the reach: optimizing screening for atrial fibrillation-the STROKESTOP III study.

Mashroor Khan, Michael Ingre, Fredrik Carlstedt, Anders Eriksson, Sofia Skröder, Johanna Star Tenn, Mårten Rosenqvist, Emma Svennberg

Abstract readClinical Trial Protocol
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Population reach and participation rate in opportunistic vs. systematic atrial fibrillation screening: STROKESTOP III.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Trial
  2. Article
  3. Review
  4. Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mashroor KhanDepartment of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Stockholm, Sweden.ORCID 0000-0003-1615-5173
Michael IngreDepartment of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Stockholm, Sweden.
Fredrik CarlstedtCentre for Clinical Research and Education, Region Värmland, Karlstad, Sweden.
Anders ErikssonDepartment of Clinical Physiology, Region Värmland, Karlstad, Sweden.
Sofia SkröderCentre for Clinical Research and Education, Region Värmland, Karlstad, Sweden.ORCID 0000-0002-6360-1167
Johanna Star TennDepartment of Clinical Physiology, Region Värmland, Karlstad, Sweden.
Mårten RosenqvistDepartment of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Danderyd, Sweden.ORCID 0000-0003-3337-9259
Emma SvennbergDepartment of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Stockholm, Sweden.ORCID 0000-0002-6413-0870

Funding

Stockholm County CouncilSwedish Heart-Lung Foundation 2022-03484
6 · The paper itself

Abstract

aimsAtrial fibrillation (AF) is the most common type of cardiac arrythmia and is an important risk factor for ischaemic stroke. Many cases of AF remain undiagnosed due to its paroxysmal, intermittent, and often asymptomatic nature. Early detection of AF through screening and initiation of treatment with oral anticoagulants can prevent stroke, increase life expectancy, and decrease the cost of healthcare for the society. However, participation has been low in previous AF screening studies employing population screening. The aim of this study is to determine whether opportunistic screening is a superior method to increase participation in comparison to population screening. We hypothesize that opportunistic screening will significantly increase participation. METHODS AND

resultsIn our study, STROKESTOP III, a randomized prospective cohort study, we compare two different methods of AF screening in high-risk individuals: population screening vs. opportunistic screening. Sixteen different primary clinics in Värmland, Sweden, serving 75-76-year-old individuals (n = 2954), will be randomized to either population screening or opportunistic screening. The individuals will be instructed to record electrocardiogram (ECG) for 30 s, 3 times daily for 2 weeks, using a handheld one-lead ECG device. Patients with detected AF will be referred to their primary healthcare physician and offered treatment. The main objective of the study is to determine the rate of participation in opportunistic screening in comparison to population screening.

conclusionsThe STROKESTOP III study will provide valuable information on which screening method to use for improved participation in atrial fibrillation screening.

Indexed as

Atrial FibrillationMass ScreeningAgedEarly DiagnosisElectrocardiographyFemaleHumansMaleProspective StudiesRandomized Controlled Trials as TopicRisk FactorsSwedenAtrial fibrillationPreventionScreeningStroke

Identifiers

PMID39298681
PMCPMC11413581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.